AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03151564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computed Tomography Scan - 70% Dose Reduction
Description: Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
Study NCT03151564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Deep Learning Image Reconstruction (DLIR)
Description: Participants to receive standard-of-care imaging without the artificial intelligence software and imaging technique.
Study NCT00408421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Study NCT00408421 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03838952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal medicine
Description: Each pack: Jia Wei Xiao Yao San granule(5 gm), Gou Teng granule (1.1 gm),and Ba Ji Tian (1.1 gm), 2 times per day for 12 weeks.
Study NCT01197560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25 mg orally for 21/28 days until Diffuse Large B-Cell Lymphoma (DLBCL) progressive disease. For patients with Creatinine Clearance ≥ 30 mL/min but \< 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
Study NCT01197560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Suggested starting doses and regimens for Gemcitabine is 1,250 mg/m\^2 intravenous (IV) administration on days 1, 8, 15 every 28 days for 6 Cycles or 1,000 mg/m\^2 IV days 1 and 15 every 28 days for 6 Cycles
Study NCT01197560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Suggested starting dose and regimen for Oxaliplatin is 100 mg/m\^2 IV day 1 for 21 days for 6 Cycles
Study NCT01197560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Suggested starting dose for Rituximab is 375 mg/m\^2 IV days 1, 8, 15, 22 during Cycle 1, and if stable disease at Week 12, also on Day 1 of Cycles 4, 6, 8, and 10 (CD20+ patients only)
Study NCT01197560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Suggested starting doses for Etoposide are:~100 mg/m\^2 IV days 1-5 every 28 days for 6 Cycles, or 100 mg/m\^2 IV days 1-3 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-21 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-14 every 28 days for 6 Cycles, or 50 mg/m\^2 oral days 1-10 every 28 days for 6 Cycles
Study NCT01941667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Messages, Virtual Home Visits
Description: Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level~Daily messages requesting weight, intake, pulse ox and pulse are automated~Virtual home visits occur twice weekly where the investigators see the infant and families.
Study NCT01154972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Preoperative sentinel lymph node identification and marking
Description: SLN is identified using gamma probe and ultrasound. Percutaneous wire placement carried out to mark SLN for subsequent surgical verification.
Study NCT01996202 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ipilumimab
Study NCT01996202 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation
Study NCT01805232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artesunate
Description: intravenous artesunate 80 mg/kg initially then after 8 hours then daily
Study NCT01805232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: artesunate
Description: intravenous artesunate 80 mg/kg initially then after 8 hours then daily
Study NCT01805232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinine
Description: quinine infusion 80 mg/kg every 8 hours till the patient can take orally
Study NCT01805232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinine
Description: quinine infusion 80 mg/kg every 8 hours till the patient can take orally
Study NCT04721236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hyperimmune plasma
Description: plasma collected from convalescent Covid-19 donors with titre 1:80 or more
Study NCT03517748 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DM05 eye drops
Description: Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
Study NCT03517748 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optive™ eye drops
Description: Ophthalmic use. One to two drops instilled in each eye from 4 to 6 times per day during 84 days of treatment.
Study NCT03111134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified component separation technique
Description: a new abdomen closure technique based on component separation technique
Study NCT03657368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low tidal Volume
Description: Tidal volume = 6 ml/kg predicted body weight
Study NCT03657368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High tidal Volume
Description: Tidal volume = 10 ml/kg predicted body weight
Study NCT03657368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low PEEP
Description: PEEP = 5 cm H2O
Study NCT03657368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High PEEP
Description: PEEP = 8 cm H2O
Study NCT03412474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: The study drugs will be prepared by an anesthesiologist not involved in performing the block, patient care or in data collection. Patients will be randomly allocated into two groups of 40 patients each:~Group A: will receive 0.2 ml/kg/side of bupivacaine (0.125%).
Study NCT03412474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Group B: will receive 0.2 ml/kg/side of bupivacaine (0.125%) + 0.5 µ/kg of dexmedetomidine.
Study NCT03412474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: paracetamol
Study NCT04489225 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational only without any intervention
Study NCT02165800 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: L-PANP-TME
Study NCT02165800 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: O-PANP-TME
Study NCT02322892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiamine
Description: 200 mg thiamine in 50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
Study NCT02322892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline solution
Description: 50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
Study NCT03495128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bed Rest
Description: 3 days of head down tilt (-6 degrees) bed rest
Study NCT03244696 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step Tracking
Description: The step tracking intervention is designed to increase physical activity through the use of self-monitoring and brief motivational materials. The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
Study NCT03244696 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water Tracking
Description: The water tracking intervention is designed to increase water intake, to a healthy level, through the use of self-monitoring and brief motivational materials.The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
Study NCT05066113 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency-Based treatment
Description: RF-based treatments use electrothermolysis to deliver heat energy to targeted structures in the skin, such as hair follicles or glands by the use of insulated needles. The investigators will use radio frequency based treatment on a pre-selected skin area (about 3cm x 3cm or 1 ¼ x 1 ¼ inches in size) on either your left or right underarm that is eligible for assessment, study treatment, and biopsy.~Participants will receive clinical assessments, photography, questionnaires, up to 3 treatments of RF-based selective electrothermolysis to pre-selected areas of the axillary skin, up to 2 4-mm skin biopsies for up to 5 study visits.
Study NCT01158196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: infra-red diode laser
Description: laser treatment of scar after keloid excision~laser treatment of surgery scar
Study NCT03181958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NHFOV
Description: Nasal high frequency oscillation ventilation (NHFOV) is used as the noninvasive supporting mode after extubation.
Study NCT03181958 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP
Description: Nasal continuous positive airway pressure(NCPAP) is used as the noninvasive supporting mode after extubation.
Study NCT03181958 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIPPV
Description: Nasal intermittent positive pressure ventilation(NIPPV) is used as the noninvasive supporting mode after extubation.
Study NCT00202358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atenolol
Study NCT00202358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03495128 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reconditioning
Description: daily resistance training (for 3 days) on one leg
Study NCT03686748 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Two-point discrimination training
Description: Patients will undergo multiple sessions of two-point discrimination training.
Study NCT01941667 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual care as defined by by the Cardiology Department.
Study NCT01109797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Social Behavioral Intervention
Description: If you are assigned to the first group, you will have two all-day Saturday sessions four weeks apart on the KU campus in Lawrence. The objectives of the Saturday programs are to promote positive behavior change with respect to taking ownership of diabetes and its demands by providing transition-specific information, enabling participants to practice the life skills needed to successfully manage diabetes as an adult, and fostering peer-to-peer social networking over the 6-month period of the intervention (and beyond). You will continue to see your current provider of diabetes care outside of the parameters of this study.
Study NCT01109797 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Transition Clinic
Description: Patients who participate in the transition clinic arm of the study will be seen six times during a six-month time period, as well as receive psychological assessment and intervention, as necessary, prior to the first clinic visit (intake) and as part of visits 2 and 4. Three of the six visits will be standard of care medical visits with either a pediatric or adult provider or both. Three will be individual or group education sessions with diabetes educators focused on transition issues such as, managing the adult health care system, talking with your care provider,and dealing with adult issues (pregnancy, genetic concerns, etc).
Study NCT03686748 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-point discrimination training
Description: Patients will undergo multiple sessions of one-point discrimination training.
Study NCT02724540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bland Embolization
Description: Lobar or segmental bland embolization with microspheres (50-500 microns) to 2-5 heartbeat stasis
Study NCT02724540 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization
Description: Lobar or segmental lipiodol transarterial chemoembolization. Doxorubicin 50 mg dissolved in 10 mL dilute contrast and emulsified with 10-20 cc iodized oil, followed by 50-500 μm microspheres.
Study NCT02724540 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug Eluting Beads Embolization
Description: CLOSED - Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU.
Study NCT05061914 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pericardial effusion drainage
Description: tamponading pericardial effusion is a life threatenning condition , pericardiocentesis is performed for patients who are vitally unstable and with a massive amount of effusion to prevent cardiac tamponade, Surgical drainage of pericardial effusion was classically conducted by either open thoracotomy or subxiphoid pericardiectomy. Thoracoscopy has established itself as an alternative to open thoracotomy for the management of many pericardial, pleural and pulmonary disorders
Study NCT00763555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD 2027
Description: Participants applied Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
Study NCT02784340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 16 mg Dexamethasone IV drip
Study NCT02784340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
Study NCT02784340 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (IV fluids)
Description: IV fluids 500 cc saline infusion
Study NCT02784340 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivicaine and Fentany
Study NCT04497831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine hydrochloride
Description: 5 mg milligram(s) per day per two days of dosage
Study NCT04497831 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhalation use
Study NCT01906632 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: DC-CIK Immunotherapy
Study NCT04649320 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: 1. 13-item questionnaire about cancer patient's distress and everyday life,~2. EORTC-QLQ-C30
Study NCT02085122 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: noninvasive ventilation
Description: Ventilatory support with bilevel positive pressure was held for 30 minutes with the volunteer sitting comfortably. A fan with two pressure levels (Vivo 40 Bi-Level, General Electric Company), which was attached to the face of the individual through a face Macara ( Respironics), was initially adopted one of 15 cmH2O IPAP and EPAP was used 5 cmH2O, making admissible pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
Study NCT00763555 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcitriol Vehicle
Description: Participants applied placebo matched to Calcitriol 3 mcg/g spray topically to the affected areas twice daily for 8 weeks.
Study NCT03645382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: baked barley powder
Description: The baked barley was consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.The baked barley powder capsule had approximately 900 mg/day, 336 mg of baked barley and 564 mg of nondigestible maltodextrin.
Study NCT03645382 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: jeju steam onion
Description: The jeju steam onion was consumed one capsules, three times daily before meals, for a total of three capsules consumed per day.The jeju steam onion capsule had approximately 900 mg/day, 336 mg of jeju steam onion powder and 564 mg of nondigestible maltodextrin.
Study NCT03203772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality
Description: Participants will engage in virtual visualization therapy in an immersive virtual reality environment
Study NCT03396874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: PET/CT imaging with 68Ga-PSMA:~68Ga-PSMA is an investigational radioactive drug that binds to receptors on prostate cancer cells. The intravenously administered drug dose will be about 5 mCi (range 3-7 mCi).
Study NCT02549846 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke
Study NCT02549846 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Statin
Description: Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke
Study NCT01063959 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Sleeve Gastrectomy
Description: Sleeve Gastrectomy was originally reported as the first step in an alternative two-staged procedure for the super obese patient to decrease morbidity, predominantly private pay.
Study NCT01063959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Sleeve Gastrectomy
Description: Sleeve Gastrectomy was originally reported as the first step in an alternative two-staged procedure for the super obese patient to decrease morbidity, predominantly private pay.
Study NCT01063959 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic Gastric Bypass
Description: Presently, the laparoscopically performed gastric bypass accounts for 80% of obesity surgery in the United States, predominantly covered by insurance.
Study NCT01063959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Gastric Bypass
Description: Presently, the laparoscopically performed gastric bypass accounts for 80% of obesity surgery in the United States, predominantly covered by insurance.
Study NCT02096484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Metacognitive Therapy
Study NCT02096484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation Therapy
Study NCT04142632 — intervention group
Intervention type: PROCEDURE
Intervention: clinical and paraclinical examination
Description: Physical examination of the penis, ultrasonography of the bladder end the testis, Biological sample for endocrine assessment
Study NCT01718730 — intervention group
Intervention type: DEVICE
Intervention: Transcranial Magnetic Stimulation (TMS)
Description: Single and paired-pulse TMS applied to the motor cortex will collect measures of cortical excitability and inhibition.
Study NCT01718730 — intervention group
Intervention type: DEVICE
Intervention: Magnetic Resonance Spectroscopy and Imaging
Description: MRS/MRI Scans will examine glutamate concentrations in the motor cortex and anterior cingulate cortex.
Study NCT03400917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-GBM-1
Description: Investigational treatment with AV-GBM-1
Study NCT02839993 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Study NCT02839993 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Study NCT04769609 — intervention group
Intervention type: DEVICE
Intervention: bioresorbable membrane
Description: reconstructive surgical treatment of peri-implant bone defects
Study NCT04335591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 75 mg linzagolix tablet
Description: For oral administration once daily
Study NCT04335591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg linzagolix tablet
Description: For oral administration once daily
Study NCT04335591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet to match 75 mg linzagolix tablet
Description: For oral administration once daily
Study NCT04335591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet to match 200 mg linzagolix tablet
Description: For oral administration once daily
Study NCT04335591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-back capsule (E2 1 mg / NETA 0.5 mg)
Description: For oral administration once daily
Study NCT04335591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule to match Add-back capsule
Description: For oral administration once daily
Study NCT01194778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 placebo sachet per day containing only sucrose during 12 weeks
Study NCT01194778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin K1
Description: 15 µg vitamin K1 per day during 12 weeks
Study NCT01194778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin K2
Description: 15 µg vitamin K2 per day during 12 weeks
Study NCT01194778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin K2
Description: 30 µg vitamin K2 per day during 12 weeks
Study NCT01194778 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin K2
Description: 45 µg vitamin K2 per day during 12 weeks